Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Array Biopharma (ARRY) Misses Q4 EPS by 2c
August 4, 2016 8:17 AM EDTArray Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $43.2 million versus the consensus estimate of $41.51 million.
Cash, cash equivalents and marketable securities were approximately $111 million and accounts receivable were approximately $39.3... More
